



**Luis Paz-Ares**

**Kontakt**

Luis Paz-Ares

## Publikationen (3)

Heinhuis K, Schilder R, O'Byrne K, Curigliano G, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Britschgi C, Paz-Ares L, Carlino M, Jörger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord J, Siu L. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial. *JAMA Oncol* 2019;1-8.

Peters S, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd F, Kurata T, Li Z, Qiu J, Kowanetz M, Mocchi S, Shankar G, Sandler A, Früh M, Ho C, Gettinger S, Johnson M, Jänne P, Garassino M, Christoph D, Toh C, Rizvi N, Chafit J, Carcereny Costa E, Patel J, Chow L, Koczywas M, Felip E. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). *J Clin Oncol* 2017; 35:2781-2789.

Kisbenedek L, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof G, Paz-Ares L, Pizzocaro G, Mead G, Mason M, Klepp O, Kliesch S, Koehrmann K, Kollmannsberger C, Kuczyk M, Laguna P, Galvis O, Loy V, Pont J, Pottek T, Powles T, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, Skakkebaek N, Sedlmayer F, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz H, Schmidberger H, Schmoll H, Schrader M, von der Maase H, Jones W, Krege S, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder P, De Santis M, de Wit M, de Wit R, Classen J, Cavallin-Stähl E, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Derigs H, Dieckmann K, Dieing A, Gillessen Sommer S, Hartmann J, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Germa-Lluch J, Gerl A, Droz J, Fenner M, Fizazi K, Flechon A, Fosså S, del Muro X, Gauler T, Geczi L, Joffe J. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. *European urology* 2008; 53:497-513.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)